IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Colorectal cancers that display reduced sensitivity to EGFR inhibition and strong IGF2 overexpression can be effectively treated by dual EGFR/IGF2 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, preclinical studies have shown that IGF2 overexpression attenuates the efficacy of cetuximab in CRC patient-derived xenografts (PDXs) [176].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“Response to cetuximab in “quadruple negative” mCRC xenopatients: A population study in 125 cases Clinical studies have recently demonstrated that, in addition to the validated KRAS mutations in exon 2, additional KRAS mutations in exons 3 and 4, as well as NRAS, BRAF, and concurrent PIK3CA (exon 20) mutations, predict…”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
Cited by
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Self-citationInterrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Self-citationGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Self-citationInsulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Metadata
- Authors
- Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L., & Bertotti, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Department of Oncology, University of Torino Medical School, 10060 Candiolo, Torino, Italy.
- Universitair Ziekenhuis Leuven (BE)
- Institute of Biostatistics and Analyses, Masaryk University, 611 37 Brno, Czech Republic.
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Corresponding author
- Zanella, Eugenia R.
- Galimi, Francesco
- Sassi, Francesco
- Trusolino, Livio
- Bertotti, Andrea
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-01-28
- Volume
- 7
- Issue
- 272
- Pages
- 272ra12-272ra12
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2144987077
- Cited by
- 117
- References
- 47
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 12 · 2018: 13 · 2017: 14 · 2016: 13 · 2015: 7
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- American Association for Cancer Research (12-20-16-BERT)
- Ministero dell'Universita e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- AIRC Investigator (14205, 11852)
- European Regional Development Fund
- Fondo per gli Investimenti della Ricerca di Base_Futuro in Ricercaq
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS
- State Budget of the Czech Republic-RECAMO (CZ.1.05/2.1.00/03.0101)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin-like growth factor II, colorectal cancer, anti-EGFR therapy, cetuximab, stable disease, patient-derived xenografts, IGF2 overexpression, combination therapy, predictive biomarkers, treatment resistance
- MeSH terms
- Cetuximab, Animals, Antineoplastic Agents, Clinical Trials as Topic, Exons, Humans, Immunohistochemistry, Insulin-Like Growth Factor II, Ligands, Mutation, Neoplasm Transplantation, Biomarkers, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. https://app.cochat.ai/papers/10.1126/scitranslmed.3010445
- The paper
- Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L., & Bertotti, A. (2015). IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3010445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.